Assessment of Oxidative Stress and Inflammatory Markers of Medical Importance in Oral Squamous Cell Carcinoma

Butt, Seema; Abbas, Umaima; Arshad, Ayesha; Ahmad, Barzan; Ashraf, Aqsa; Haseeb, Muhammad; Butt, Arif Nazir; Rana, MA; Hafeez, MM

doi:10.54112/bcsrj.v2022i1.91

Cited by 2 publications

(2 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The use of cell lysate could be an effective cell-free treatment for different diseases. Without direct contact of live cells on the host tissue, the treatment of cell lysate exposes the tissue to various soluble components present in MSCs, e.g., growth factors, cytokines, and microvesicles holding micro RNAs Yeghiazarians et al, 2009;Zafar et al, 2022;Afzal et al, 2022;Noor et al, 2022;Butt et al, 2022). The study aimed to investigate the loading of NLC with BMSCs lysate and its role in reducing inflammation in-vitro and in-vivo for the first time.…”

Section: Inflammation Reduction Potential Of Nanostructured Lipid Car...mentioning

confidence: 99%

Inflammation reduction potential of nanostructured lipid carriers encapsulated with rat’s bone marrow cells’ lysate

et al. 2022

View full text Add to dashboard Cite

Bone marrow-derived mesenchymal stromal cells (BMSCs) have been used for treating inflammatory disorders. Due to the large size of BMSCs compared to nanoparticles, BMSCs cannot be loaded into the nanoparticles. It is hypothesized that BMSCs lysate loading into the nanocarriers will effectively deliver cellular contents and regulatory elements of BMSCs at the injury site. This study aimed to investigate nanostructured lipid carriers (NLC) loading with BMSCs lysate through basic characterization and morphological analysis. Moreover, this study was mainly designed to investigate the role of NLC loaded BMSCs lysate in reducing inflammation via in-vitro and in-vivoassays. The in-vitro study involves cell viability assays, p53, annexin V and VEGF expression through ELISA and immunocytochemistry, real-time BAX, caspase-3, IL-6, IL-8, TOP2A, PCNA, and Ki-67 gene expression analysis. Additionally, to evaluate in-vivo anti-inflammatory activity, the carrageenan-induced rat paw oedema model was used. In-vitro results showed that NLC loaded BMSCs lysate increased cell viability, decreased apoptosis and pro-inflammatory genes expression and up-regulated angiogenesis and proliferation in H2O2 pre-stimulated cells. Findings of the in-vivo assay also indicated a reduction in rat's paw oedema volume in NLC-loaded BMSCs lysate, and downregulation of BAX, Caspase-3, IL-6, and IL-8 was observed. Enhanced expressions of TOP2A, PCNA, and Ki-67 were obtained. Concluding the results of this study, NLC-loaded BMSCs lysate could reduce inflammation and possibly regenerate damaged tissue mainly via increasing cell viability, angiogenesis and proliferation, and reducing apoptosis and pro-inflammatory cytokines.

show abstract

Section: Inflammation Reduction Potential Of Nanostructured Lipid Car...mentioning

confidence: 99%

Inflammation reduction potential of nanostructured lipid carriers encapsulated with rat’s bone marrow cells’ lysate

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Mineral bone disease is a clinical disease linked to CKD defined by abnormalities of calcium, phosphorus, PTH and vitamin D metabolism. This also included anomalies in bone turnover, mineralization, linear development, and strength 3,4 .…”

Section: Introductionmentioning

confidence: 99%

Prevalence of Bone Mineral Disorder in Hemodialysis patients: A Single Centered Study of Local Population

Nasim¹,

Rafique²,

Talal³

et al. 2022

PJMHS

View full text Add to dashboard Cite

Background: Mineral homeostasis deteriorates when kidney function diminishes, manifesting as variations in blood and tissue levels of calcium and phosphate, followed by the change in circulating parathyroid hormone (PTH). Mineral bone disorders (MBD) are a clinical illness caused by chronic renal disease that expresses as a systemic impairment of mineral and bone metabolism. Aim: To find out prevalence of bone mineral disorders in hemodialysis patients presenting in Nephrology Ward, SIMS. Lahore Methodology: This observational analysis included a total of 88 patients, who were on dialysis at the nephrology department of SHL for the period of more than six months. The study was conducted from 17 September 2021 to 10 March 2022 after the approval of the ethical review board of the Department. According to their blood PTH levels, the patients were split into three groups: those with PTH levels less than 150 pg/ml (low bone turnover), those with PTH levels between 150 and 300 pg/ml (normal bone turnover), and those with PTH levels greater than 300 pg/ml (high bone turnover). Results: The prevalence of bone mineral disorder was 87.5% in hemodialysis patients presenting at the nephrology department, in which prevalence of high turnover bone disorder was 73.9% whereas the prevalence of low turnover bone disorder was 13.6%. In the early dialysis period (0.5-5 years) the prevalence of bone mineral disorders was more prominent as compared to the patients on dialysis for more than 5 years. Conclusion: There was a high prevalence of bone mineral disorders, in which patients with high turnover were found to be more prevalent. Similarly, patients in the early years of dialysis are more prone to develop bone mineral disorders. Thus, we should keep these findings in mind while doing the follow up and adjust the medication accordingly. Keywords: Bone Mineral Disorders, Low Turnover Bone Disorders, Hyper Para Thyroid Disorder, Prevalence of Disease

show abstract

Assessment of Oxidative Stress and Inflammatory Markers of Medical Importance in Oral Squamous Cell Carcinoma

Cited by 2 publications

References 19 publications

Inflammation reduction potential of nanostructured lipid carriers encapsulated with rat’s bone marrow cells’ lysate

Inflammation reduction potential of nanostructured lipid carriers encapsulated with rat’s bone marrow cells’ lysate

Prevalence of Bone Mineral Disorder in Hemodialysis patients: A Single Centered Study of Local Population

Contact Info

Product

Resources

About